Form 6K Evotec SE ADR For: 24 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evotec AG O.N. (EVTG)
The Evotec AG share price today is 5.165, view ETR EVTG stock exchange data. Track the latest Evotec AG share price with real-time updates on EVTG stock performance including market cap, day range, 52-week range and dividend yield. Access EVTG charts, earnings dates and analyst estimates to support your investment decisions.
5.165
+0.025(+0.49%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.110
5.165
52 wk Range
3.995
8.566
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.1105.165
52 wk Range
3.9958.566
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
EVTG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
6.833
Upside
+32.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Form 6K Evotec SE ADR For: 24 April
- Investing.com
- Evotec SE ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Compare EVTG to Peers and Sector
Metrics to compare | EVTG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVTGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | 1.1x | −0.5x | |
PEG Ratio | −0.19 | −0.11 | 0.00 | |
Price/Book | 1.1x | 2.3x | 2.6x | |
Price / LTM Sales | 1.2x | 5.4x | 3.2x | |
Upside (Analyst Target) | 20.6% | 96.9% | 48.8% | |
Fair Value Upside | Unlock | 15.2% | 7.6% | Unlock |
Analyst Ratings
4 Buy
3 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.833
(+32.30% Upside)
Earnings
Latest Release
08-04-2026
EPS / Forecast
0.08 / 0.05
Revenue / Forecast
253.27M / 245.69M
FAQ
What Is the Evotec AG (EVTG) Share Price Today?
The Evotec AG share price today is 5.165.
What is the current Evotec AG (EVTG) share price and day range?
As of 29-04-2026, the Evotec AG share price is 5.165, with a previous close of 5.140. The share price has ranged from 5.110 to 5.165 today, while the 52-week range spans from 3.995 to 8.566.
What Is the Evotec AG Market Cap?
As of today, Evotec AG market cap is 917.190M.
What Is the Evotec AG (EVTG) Share Price Target?
The average 12-month share price target for Evotec AG is 6.833, with a high estimate of 10 and a low estimate of 4.4. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +32.30% Upside potential.
What Is Evotec AG's Earnings Per Share (TTM)?
The Evotec AG EPS (TTM) is -0.583.
When Is the Next Evotec AG Earnings Date?
Evotec AG will release its next earnings report on 06-05-2026.
From a Technical Analysis Perspective, Is EVTG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does Evotec AG Trade On?
Evotec AG is listed and trades on the Frankfurt Stock Exchange.
What Is the Stock Symbol for Evotec AG?
The stock symbol for Evotec AG is "EVTG."
How Many Times Has Evotec AG Stock Split?
Evotec AG has split 2 times.
How Many Employees Does Evotec AG Have?
Evotec AG has 4467 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.